Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy

Epilepsy Research

Volumn 104, Issue 1-2, 2013, Pages 134-139

  Koo, Dae Lim ^a   Joo, Eun Yeon ^a   Kim, Daeyoung ^a   Hong, Seung Bong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bone mineral density; Epilepsy; Levetiracetam

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; ETIRACETAM; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE STRENGTH; DOSE RESPONSE; DRUG MEGADOSE; EPILEPSY; FEMALE; HUMAN; LOW DRUG DOSE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTICONVULSANTS; BIOLOGICAL MARKERS; BONE DENSITY; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PIRACETAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875522173     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.09.002     Document Type: Article

References (43)

1. Abou-Khalil B. Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf. 2005, 28:871-890.
2. Ali Il H.N., Horrigan T., Kellough L., Tietjen G.E. Measurement of bone mineral density in patients on levetiracetam monotherapy. Am. Epilepsy Soc. Abstr. 2006, 2:150.
3. Andress D.L., Ozuna J., Tirschwell D., Grande L., Johnson M., Jacobson A.F., Spain W. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch. Neurol. 2002, 59:781-786.
4. Babacan O., Karaoglu A., Vurucu S., Yesilkaya E., Yesilyurt O., Cayci T., Gulgun M., Unay B., Akin R., Ozcan O. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism?. J. Clin. Neurol. 2012, 8:65-68.
5. Babayigit A., Dirik E., Bober E., Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr. Neurol. 2006, 35:177-181.
6. Beniczky S.A., Viken J., Jensen L.T., Andersen N.B. Bone mineral density in adult patients treated with various antiepileptic drugs. Seizure 2012, 21:471-472.
7. Boluk A., Guzelipek M., Savli H., Temel I., Ozisik H.I., Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol. Res. 2004, 50:93-97.
8. Cansu A., Yesilkaya E., Serdaroglu A., Hirfanoglu T.L., Camurdan O., Gulbahar O., Gucuyener K., Cinaz P. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr. Neurol. 2008, 39:266-271.
9. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000, 55:236-242.
10. Cummings S.R., Nevitt M.C., Browner W.S., Stone K., Fox K.M., Ensrud K.E., Cauley J., Black D., Vogt T.M. Risk factors for hip fracture in white women Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 1995, 332:767-773.
11. Dymling J.F., Lidgren L., Walloe A. Biochemical variables related to calcium metabolism in epileptics. Acta Med. Scand. 1979, 205:401-404.
12. Ecevit C., Aydogan A., Kavakli T., Altinoz S. Effect of carbamazepine and valproate on bone mineral density. Pediatr. Neurol. 2004, 31:279-282.
13. El-Hajj Fuleihan G., Dib L., Yamout B., Sawaya R., Mikati M.A. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 2008, 43:149-155.
14. Ensrud K.E., Walczak T.S., Blackwell T.L., Ensrud E.R., Barrett-Connor E., Orwoll E.S. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008, 71:723-730.
15. Farhat G., Yamout B., Mikati M.A., Demirjian S., Sawaya R., El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 2002, 58:1348-1353.
16. Hahn T.J., Scharp C.R., Richardson C.A., Halstead L.R., Kahn A.J., Teitelbaum S.L. Interaction of diphenylhydantoin (phenytoin) and phenobarbital with hormonal mediation of fetal rat bone resorption in vitro. J. Clin. Invest. 1978, 62:406-414.
17. Hans D., Downs R.W., Duboeuf F., Greenspan S., Jankowski L.G., Kiebzak G.M., Petak S.M. Skeletal sites for osteoporosis diagnosis: the 2005 ISCD Official Positions. J. Clin. Densitom. 2006, 9:15-21.
18. Heo K., Rhee Y., Lee H.W., Lee S.A., Shin D.J., Kim W.J., Song H.K., Song K., Lee B.I. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy. Epilepsia 2011, 52:1884-1889.
19. Kim S.H., Lee J.W., Choi K.G., Chung H.W., Lee H.W. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 2007, 10:291-295.
20. Kruse R. Osteopathies in antiepileptic long-term therapy (preliminary report). Monatsschr. Kinderheilkd. 1968, 116:378-381.
21. Kumandas S., Koklu E., Gumus H., Koklu S., Kurtoglu S., Karakukcu M., Keskin M. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3. J. Pediatr. Endocrinol. Metab. 2006, 19:529-534.
22. Lukyanetz E.A., Shkryl V.M., Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002, 43:9-18.
23. Lyseng-Williamson K.A. Levetiracetam: a review of its use in epilepsy. Drugs 2011, 71:489-514.
24. Lyseng-Williamson K.A. Spotlight on levetiracetam in epilepsy. CNS Drugs 2011, 25:901-905.
25. Mintzer S., Boppana P., Toguri J., DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 2006, 47:510-515.
26. Mosekilde L., Hansen H.H., Christensen M.S., Lund B., Sorensen O.H., Melsen F., Norman A.W. Fractional intestinal calcium absorption in epileptics on anticonvulsant therapy. Short-term effect of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol. Acta Med. Scand. 1979, 205:405-409.
27. Nilsson O.S., Lindholm T.S., Elmstedt E., Lindback A., Lindholm T.C. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch. Orthop. Trauma Surg. 1986, 105:146-149.
28. Nissen-Meyer L.S., Svalheim S., Tauboll E., Gjerstad L., Reinholt F.P., Jemtland R. How can antiepileptic drugs affect bone mass, structure and metabolism? Lessons from animal studies. Seizure 2008, 17:187-191.
29. Nissen-Meyer L.S., Svalheim S., Tauboll E., Reppe S., Lekva T., Solberg L.B., Melhus G., Reinholt F.P., Gjerstad L., Jemtland R. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007, 48:1850-1860.
30. Pack A.M., Morrell M.J. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001, 15:633-642.
31. Pack A.M., Morrell M.J., Marcus R., Holloway L., Flaster E., Done S., Randall A., Seale C., Shane E. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann. Neurol. 2005, 57:252-257.
32. Pack A.M., Morrell M.J., Randall A., McMahon D.J., Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008, 70:1586-1593.
33. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 2005, 115:3318-3325.
34. Sheth R.D., Hermann B.P. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr. Neurol. 2007, 37:250-254.
35. Sotaniemi E.A., Hakkarainen H.K., Puranen J.A., Lahti R.O. Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy. Ann. Intern. Med. 1972, 77:389-394.
36. Souverein P.C., Webb D.J., Petri H., Weil J., Van Staa T.P., Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 2005, 46:304-310.
37. Souverein P.C., Webb D.J., Weil J.G., Van Staa T.P., Egberts A.C. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006, 66:1318-1324.
38. Stephen L.J., McLellan A.R., Harrison J.H., Shapiro D., Dominiczak M.H., Sills G.J., Brodie M.J. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999, 8:339-342.
39. Takahashi A., Onodera K., Kamei J., Sakurada S., Shinoda H., Miyazaki S., Saito T., Mayanagi H. Effects of chronic administration of zonisamide, an antiepileptic drug, on bone mineral density and their prevention with alfacalcidol in growing rats. J. Pharmacol. Sci. 2003, 91:313-318.
40. Valimaki M.J., Tiihonen M., Laitinen K., Tahtela R., Karkkainen M., Lamberg-Allardt C., Makela P., Tunninen R. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J. Bone Miner. Res. 1994, 9:631-637.
41. Verrotti A., Coppola G., Parisi P., Mohn A., Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin. Neurol. Neurosurg. 2010, 112:1-10.
42. Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics and sedatives and risk of fractures: effects of half-life. Calcif. Tissue Int. 2008, 82:34-43.
43. Vestergaard P., Tigaran S., Rejnmark L., Tigaran C., Dam M., Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol. Scand. 1999, 99:269-275.